Abstract
Abstract. This article provides a detailed overview of the current state of acute leukemia treatment, encompassing chemotherapy, molecular-targeted therapy, bone marrow transplantation, and the evolving role of personalized medicine. It delves into standard chemotherapy regimens, their efficacy, and adverse effects, highlighting the challenges posed by resistance and relapses. The significant impact of molecular-targeted therapy, including tyrosine kinase inhibitors and FLT3 inhibitors, is examined, along with their integration with traditional chemotherapy. The article also discusses bone marrow transplantation, comparing allogeneic and autologous transplants and conditioning regimens. Personalized medicine, driven by genetic profiling and the emergence of novel therapies like CAR-T and immunomodulatory drugs, is explored for its potential to revolutionize treatment approaches. The global trends in acute leukemia, including epidemiological shifts and disparities in access to care, are analyzed, alongside the economic aspects influencing treatment accessibility and policy decisions. This comprehensive review underscores the multifaceted nature of acute leukemia treatment and the ongoing efforts to enhance patient outcomes while addressing global disparities in care.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call